Xilio Therapeutics to Present at Upcoming Investor Conferences
February 27, 2023 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
February 16, 2023 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
February 02, 2023 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
November 23, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
November 09, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with...
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
November 04, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
September 22, 2022 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
September 15, 2022 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
August 09, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
XTX101, tumor-selective anti-CTLA-4, has successfully reached dose levels exceeding the target dose with limited active (unmasked) molecule in the periphery in ongoing Phase 1 clinical trial ...